To see the effect of Shadbindu Tail Nasya and Shirahshooladivajra Rasa Orally in Aradhavabhedaka (Migraine)

Evaluation of Shadbindu Tail Nasya and Shirahshooladivajra Rasa Orally in Aradhavabhedaka(Migraine)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/07/034945

Enrollment

Registered

2021-07-16

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G43- Migraine

Interventions

Intervention1: In Group A, Patients will be given Shadbindu Tail Nasya.: Nasyam in nose 6 drop in each nostril once in a day There will be 2 sittings of Nasya in 30 days. First sitting - 7 days (1st -

Eligibility

Inclusion criteria

Inclusion criteria: Patients with classical symptoms of Ardhavabhedaka(Migraine). Patients in related group who are fit for Nasya Karma.

Exclusion criteria

Exclusion criteria: Patients less than 18 years and above 45 years of age. Patients in related group who are contraindicated for Nasya Karma. Patients suffering from any other forms of headaches apart from Ardhavabhedaka (Migraine). Patient suffering from any systemic diseases and receiving medication which may alter the results of study.

Design outcomes

Primary

Measure	Time frame
Subjective Parameters - Severity of Headache Frequency of Headache Duration of Headache Nausea Vomiting Vertigo AuraTimepoint: Before intervention of Shadbindu Tail Nasya and Shirahshooladivajra Rasa Orally	—

Secondary

Measure	Time frame
Subjective Parameters - Severity of Headache Frequency of Headache Duration of Headache Nausea Vomiting Vertigo AuraTimepoint: After intervention of Shadbindu Tail Nasya and Shirahshooladivajra Rasa Orally	—

Countries

India

Contacts

Public ContactDr Jyoti Gupta

Patanjali Bhartiya Ayurvijyan Evam Anusandhan Sansthan, Haridwar

jyotiguptania@gmail.com9997907340

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026